Bulletin
Investor Alert

London Markets Open in:

Gilead Sciences Inc.

NAS: GILD

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 26, 2022, 7:59 p.m.

/zigman2/quotes/210293917/composite

$

64.40

Change

-0.07 -0.11%

Volume

Volume 388,121

Quotes are delayed by 20 min

/zigman2/quotes/210293917/composite

Previous close

$ 65.01

$ 64.47

Change

-0.54 -0.83%

Day low

Day high

$64.46

$65.46

Open

52 week low

52 week high

$57.19

$74.12

Open

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology,...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987, and is headquartered in Foster City, CA.

Valuation

P/E Current

13.18

P/E Ratio (with extraordinary items)

18.17

P/E Ratio (without extraordinary items)

14.72

Price to Sales Ratio

3.35

Price to Book Ratio

4.32

Price to Cash Flow Ratio

8.05

Enterprise Value to EBITDA

8.28

Enterprise Value to Sales

3.69

Efficiency

Total Asset Turnover

0.40

Liquidity

Current Ratio

1.27

Quick Ratio

1.13

Cash Ratio

0.64

Profitability

Gross Margin

75.88

Operating Margin

37.27

Pretax Margin

30.24

Net Margin

22.74

Return on Assets

9.13

Return on Equity

31.70

Return on Total Capital

20.67

Capital Structure

Total Debt to Total Assets

40.15

Officers and Executives

Name Age Officer Since Title
Mr. Daniel P. O'Day 56 2019 Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson 49 2016 Chief Financial Officer
Dr. Merdad V. Parsey - 2019 Chief Medical Officer
Dr. Flavius Martin - 2021 Executive Vice President-Research
Ms. Johanna Mercier 50 2019 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/05/2022 Kevin E. Lofton
Director
2,444   Award at $0 per share. 0
05/05/2022 Jacqueline K. Barton
Director
2,444   Award at $0 per share. 0
05/05/2022 Harish M. Manwani
Director
2,444   Award at $0 per share. 0
05/05/2022 Javier J. Rodriguez
Director
2,444   Award at $0 per share. 0
05/05/2022 Anthony Welters
Director
2,444   Award at $0 per share. 0
05/05/2022 Jeffrey A. Bluestone
Director
2,444   Award at $0 per share. 0
05/05/2022 Harish M. Manwani
Director
477   Derivative/Non-derivative trans. at $61.35 per share. 29,263
05/03/2022 Kevin E. Lofton
Director
2,223   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Jacqueline K. Barton
Director
2,223   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Harish M. Manwani
Director
2,223   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Javier J. Rodriguez
Director
2,223   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Anthony Welters
Director
2,223   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Jeffrey A. Bluestone
Director
2,223   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Sandra J. Horning
Director
1,112   Derivative/Non-derivative trans. at $0 per share. 0
05/03/2022 Harish M. Manwani
Director
349   Derivative/Non-derivative trans. at $60.33 per share. 21,055
04/28/2022 Kevin E. Lofton
Director
16,322   Derivative/Non-derivative trans. at $25.62 per share. 418,169
03/11/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
3,634   Disposition at $58.24 per share. 211,644
03/10/2022 Daniel P. O'Day
Chairman & CEO; Director
11,052   Derivative/Non-derivative trans. at $57.92 per share. 640,131
03/10/2022 Andrew D. Dickinson
Chief Financial Officer
3,602   Derivative/Non-derivative trans. at $57.92 per share. 208,627
03/10/2022 Merdad V. Parsey
Chief Medical Officer
3,505   Derivative/Non-derivative trans. at $57.92 per share. 203,009
03/10/2022 Johanna Mercier
Chief Commercial Officer
3,221   Derivative/Non-derivative trans. at $57.92 per share. 186,560
03/10/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
2,089   Derivative/Non-derivative trans. at $57.92 per share. 120,994
03/10/2022 Diane E. Wilfong
SVP, Controller & CAO
935   Derivative/Non-derivative trans. at $57.92 per share. 54,155
03/10/2022 Daniel P. O'Day
Chairman & CEO; Director
13,203   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Daniel P. O'Day
Chairman & CEO; Director
10,800   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Andrew D. Dickinson
Chief Financial Officer
4,108   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Andrew D. Dickinson
Chief Financial Officer
3,025   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Andrew D. Dickinson
Chief Financial Officer
768   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Merdad V. Parsey
Chief Medical Officer
4,157   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Merdad V. Parsey
Chief Medical Officer
3,455   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Johanna Mercier
Chief Commercial Officer
3,962   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Johanna Mercier
Chief Commercial Officer
3,025   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
3,130   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
2,593   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Diane E. Wilfong
SVP, Controller & CAO
1,272   Derivative/Non-derivative trans. at $0 per share. 0
03/10/2022 Diane E. Wilfong
SVP, Controller & CAO
2,025   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2022 Daniel P. O'Day
Chairman & CEO; Director
23,245   Derivative/Non-derivative trans. at $60.26 per share. 1,400,743
03/01/2022 Daniel P. O'Day
Chairman & CEO; Director
42,922   Derivative/Non-derivative trans. at $0 per share. 0
03/01/2022 Daniel P. O'Day
Chairman & CEO; Director
11,362   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2022 Andrew D. Dickinson
Chief Financial Officer
348   Award at $52.13 per share. 18,141
02/15/2022 Merdad V. Parsey
Chief Medical Officer
348   Award at $52.13 per share. 18,141
02/15/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
348   Award at $52.13 per share. 18,141
02/09/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
1,691   Disposition at $63.89 per share. 108,037
02/06/2022 Andrew D. Dickinson
Chief Financial Officer
767   Derivative/Non-derivative trans. at $63.9 per share. 49,011
02/06/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
1,036   Derivative/Non-derivative trans. at $63.9 per share. 66,200
02/06/2022 Diane E. Wilfong
SVP, Controller & CAO
520   Derivative/Non-derivative trans. at $63.9 per share. 33,228
02/06/2022 Andrew D. Dickinson
Chief Financial Officer
1,817   Derivative/Non-derivative trans. at $0 per share. 0
02/06/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
2,727   Derivative/Non-derivative trans. at $0 per share. 0
02/06/2022 Diane E. Wilfong
SVP, Controller & CAO
1,864   Derivative/Non-derivative trans. at $0 per share. 0
02/01/2022 Brett A. Pletcher
EVP,Corp Affairs & Gen Counsel
14,061   Disposition at $68.54 per share. 963,740
/news/latest/company/us/gild

MarketWatch News on GILD

  1. New Roche Cancer Data Slams Biopharma Stocks

    10:38 a.m. May 11, 2022

    - Josh Nathan-Kazis

  2. FDA formally approves Gilead's Veklury for young children

    2:20 p.m. April 25, 2022

    - Jaimy Lee

  3. U.S. Stocks Poised to Open Lower on Monday

    6:39 p.m. April 24, 2022

    - Janet H. Cho

  4. Yes, You Can Get Dividend Yields Around 5%. Just Be Careful.

    5:25 p.m. April 24, 2022

    - Lawrence C. Strauss

  5. 6 Defensive Healthcare Stocks With High Dividend Yields

    7:31 p.m. April 20, 2022

    - Josh Nathan-Kazis

  6. Sierra Oncology Soars After Takeover by Glaxo

    9:40 a.m. April 13, 2022

    - Lina Saigol

  7. 8 S&P 500 Stocks That Are Still Negative Since the Pandemic Lows

    10:41 a.m. March 27, 2022

    - Connor Smith

  8. Covid-19 Cases Climb in U.K. as BA.2 Spreads

    1:39 p.m. March 12, 2022

    - Josh Nathan-Kazis

  9. Loading more headlines...
/news/nonmarketwatch/company/us/gild

Other News on GILD

  1. Biotech Founder Arrested in Murder-for-Hire Scheme

    6:06 p.m. May 25, 2022

    - Joseph Walker

  2. Are Stocks In A Bear Market? What Investors Should Know

    11:45 a.m. May 23, 2022

    - Seeking Alpha

  3. Recent Stock Purchase May 2022

    5:41 p.m. May 19, 2022

    - Seeking Alpha

  4. Galapagos: Can The Company Turn Around?

    1:18 p.m. May 19, 2022

    - Seeking Alpha

  5. DOHENY ASSET MANAGEMENT /CA Buys 2, Sells 3 in 1st Quarter

    7:00 p.m. May 18, 2022

    - GuruFocus.com

  6. Loading more headlines...

At a Glance

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, California 94404

Phone

1 6505743000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$27.37B

Net Income

$6.23B

Employees

14,400

/news/pressrelease/company/us/gild

Press Releases on GILD

  1. Gilead Sciences GILD Proactive Strategies

    7:24 p.m. May 22, 2022

    - Stock Traders Daily

  2. Nasdaq 100 Movers: GILD, LCID

    10:45 a.m. May 13, 2022

    - MarketNewsVideo.com

  3. Gilead Sciences GILD Trading Report

    11:36 p.m. May 12, 2022

    - Stock Traders Daily

  4. Gilead Sciences GILD Trading Signals

    7:21 a.m. May 3, 2022

    - Stock Traders Daily

  5. Top Pharmaceutical Stocks To Watch In May 2022

    9:45 a.m. April 30, 2022

    - StockMarket.com

  6. Gilead Sciences Announces First Quarter 2022 Financial Results

    4:02 p.m. April 28, 2022

    - BusinessWire - BZX

  7. Loading more headlines...
Link to MarketWatch's Slice.